DGX

Quest Diagnostics (DGX), a major U.S. diagnostic information services provider, is highlighted as a stock to watch with a #3 (Hold) Zacks Rank and an A VGM Score. The company shows strong momentum with shares up 2.8% over four weeks and an average earnings surprise of +6.2%, making it noteworthy for momentum investors despite its Hold rating.

Quest Diagnostics (DGX) reported Q3 2026 adjusted earnings of $3.00 per share (up 15.4% YoY) and revenues of $3.10 billion (up 10% YoY), both beating consensus estimates. The company raised full-year 2026 revenue guidance to $12.065-$12.105 billion and adjusted EPS outlook to $11.25-$11.35.

Despite strong results, DGX shares fell 1.6% in pre-market trading. Operating margins improved 40 basis points to 16.7%, driven by strong testing demand and organic requisition volume growth of 14.4%.

Quest Diagnostics reported Q3 2026 earnings of $3.00 per share, beating consensus estimates of $2.85 and surpassing revenue expectations at $3.1 billion. The company has beaten EPS estimates in four consecutive quarters.

However, the stock received a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market. The Medical - Outpatient and Home Healthcare industry ranks in the top 31% of Zacks industries.

Zacks Research showcased strong performance across its various investment portfolios and rating systems during the week ended October 2, 2026. Multiple stocks received upgrades and delivered significant gains, including CRCT and PGEN surging 32% and 30.8% respectively following recommendation upgrades. The Zacks Rank #1 portfolio outperformed the S&P 500 by 2.3 percentage points year-to-date, while the Focus List portfolio returned 19.86% versus 13.14% for the S&P 500 through August 31, 2026.